The first of these targeted scavenger receptor SCARB-1 in HCV cell entry in the context of liver transplantation127and the second is an early-phase clinical trial currently underway, targeting the scavenger receptor stabilin-1 on TAMs in solid tumors, including HCC.176In addition, scavenger receptors have also been explored as biomarkers of disease states, and here we highlight their potential as biomarkers in different etiologies of liver disease (Fig. 2). This evidence concerns the gene STAB1 and hepatocellular carcinoma.